A phase III Randomised Controlled Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Aug 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

04 Jul 2022 Results of meta analysis from KEYNOTE-564, S-TRAC, ASSURE, PROTECT, ATLAS, and SORCE, presented at the 37th Congress of the European Association of Urology
16 May 2022 Systemic and meta-analysis from six trials (KEYNOTE-564, S-TRAC, ASSURE, PROTECT, ATLAS, and SORCE) presented at the 117th Annual Meeting of the American Urological Association
12 Nov 2017 Results (n=233) assessing survival benefits in subgroup of patients in SORCE trial, published in the Annals of Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com